(a) The GEPIA database demonstrated that MBOAT2 expression is remarkably higher in pancreatic adenocarcinoma (PAAD), breast invasive carcinoma (BRCA), cholangio carcinoma (CHOL), prostate adenocarcinoma (PRAD), pheochromocytoma and paraganglioma (PCPG), and brain lower-grade glioma (LGG). (b) The GEPIA database indicated that the MBOAT2 level is notably lower in neoplasm diffuse large B-cell lymphoma (DLBC), kidney renal clear cell carcinoma (KIRC), kidney chromophobe (KICH), acute myeloid leukemia (LAML), thymoma (THYM), and skin cutaneous melanoma (SKCM). P-values were determined by Non-parametric Mann-Whitney U-test in (a) and (b) (∗P < 0.05).